Aliases & Classifications for Prostatitis

MalaCards integrated aliases for Prostatitis:

Name: Prostatitis 12 76 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:14654
ICD10 33 N41 N41.9
ICD9CM 35 601 601.9
MeSH 44 D011472
NCIt 50 C26866
UMLS 73 C0033581

Summaries for Prostatitis

MalaCards based summary : Prostatitis is related to prostate sarcoma and prostate cancer, and has symptoms including prostatism An important gene associated with Prostatitis is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Acetaminophen and Cycloserine have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and endothelial, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 Prostatitis is inflammation of the prostate gland. Prostatitis is classified into acute, chronic,... more...

Related Diseases for Prostatitis

Diseases related to Prostatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 966)
# Related Disease Score Top Affiliating Genes
1 prostate sarcoma 34.6 KLK3 NKX3-1
2 prostate cancer 33.3 KLK3 MSMB NKX3-1 PROS1 TGFB1 VDR
3 chronic kidney failure 31.8 IL6 TGFB1 VDR
4 kaposi sarcoma 30.9 CXCL8 IL6 TNF
5 alpha-2-macroglobulin deficiency 30.2 KLK3 PROS1
6 breast disease 30.1 KLK3 TGFB1 TNF
7 spinal cord injury 30.1 IL6 TGFB1 TNF
8 cystitis 30.0 CXCL8 IL6 TNF
9 choroiditis 29.8 IL10 TNF
10 posterior urethral valves 29.7 IL6 TGFB1 TNF
11 oral tuberculosis 29.6 IL2 TNF
12 conjunctivitis 29.6 CXCL8 IL2 IL6
13 microscopic polyangiitis 29.5 IL10 TNF
14 osteoarthritis 29.5 IL1B IL6 TGFB1 TNF
15 melioidosis 29.3 IL10 IL6 TNF
16 fasciitis 29.3 CXCL8 IL6 TNF
17 pouchitis 29.1 CXCL8 IL10
18 exanthem 29.0 IL2 IL6 TNF
19 obstructive jaundice 29.0 CXCL8 IL6 TNF
20 acute pyelonephritis 29.0 CXCL8 IL10 IL6
21 necrotizing fasciitis 29.0 CXCL8 IL2 IL6
22 myeloma, multiple 28.9 CXCL8 IL2 IL6 TNF
23 esophagitis 28.9 CXCL8 IL1B IL6
24 schistosomiasis 28.9 IL10 IL2 TNF
25 echinococcosis 28.9 IL10 IL6 TNF
26 reactive arthritis 28.8 IL10 IL6 TNF
27 vaginitis 28.8 CXCL8 IL1B IL6
28 pulmonary tuberculosis 28.8 IL10 IL2 TNF VDR
29 arteries, anomalies of 28.6 IL1B IL6 TNF
30 laryngitis 28.5 IL1B IL6 TGFB1 TNF
31 paracoccidioidomycosis 28.5 IL10 IL2 IL6 TNF
32 fatty liver disease 28.5 IL1B IL6 TNF
33 myasthenia gravis 28.4 IL10 IL2 TNF
34 osteoporosis 28.3 IL1B IL6 TGFB1 TNF VDR
35 bone disease 28.3 IL1B IL6 TNF VDR
36 endocarditis 28.2 CXCL8 IL10 IL6 TNF
37 haemophilus influenzae 28.2 CXCL8 IL1B TNF
38 periodontal disease 28.1 CXCL8 IL1B IL6 TNF
39 filariasis 28.0 IL10 IL2 IL6 TNF
40 osteomyelitis 28.0 CXCL8 IL1B IL6 TNF
41 alcoholic hepatitis 28.0 CXCL8 IL10 IL6 TNF
42 wegener granulomatosis 28.0 CXCL8 IL10 IL6 TNF
43 q fever 28.0 IL10 IL1B TNF
44 synovitis 27.9 CXCL8 IL1B IL6 TNF
45 leishmaniasis 27.8 IL10 IL1B TNF
46 human immunodeficiency virus type 1 27.8 IL10 IL2 IL6 TNF
47 gingivitis 27.7 CXCL8 IL1B IL6 TNF
48 monocytic leukemia 27.6 CXCL8 IL1B IL6 TNF
49 pulmonary fibrosis, idiopathic 27.6 CXCL8 IL1B TGFB1 TNF
50 chlamydia 27.4 CXCL8 IL10 IL1B IL6 TNF

Comorbidity relations with Prostatitis via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Chronic Myocardial Ischemia Epididymo-Orchitis
Ischemic Heart Disease Prostate Calculus
Prostate Cancer Prostatic Hypertrophy
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatitis:



Diseases related to Prostatitis

Symptoms & Phenotypes for Prostatitis

UMLS symptoms related to Prostatitis:


prostatism

GenomeRNAi Phenotypes related to Prostatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 TGFB1 TNF ADRA1A CXCL8 IL10 IL1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 TGFB1 TNF ADRA1A CXCL8 IL10 IL1B

MGI Mouse Phenotypes related to Prostatitis:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.16 IL1B IL2 PROS1 ADRA1A IL6 IL10
2 homeostasis/metabolism MP:0005376 10.13 IL10 IL1B NKX3-1 IL2 ADRA1A IL6
3 endocrine/exocrine gland MP:0005379 10.08 MSMB NKX3-1 IL2 IL6 IL10 TNF
4 hematopoietic system MP:0005397 10.06 IL6 IL10 IL1B IL2 TNF PROS1
5 digestive/alimentary MP:0005381 10.04 NKX3-1 IL2 IL6 IL10 VDR TGFB1
6 mortality/aging MP:0010768 10.02 IL6 IL10 IL1B NKX3-1 IL2 ADRA1A
7 integument MP:0010771 9.95 IL6 IL10 IL1B TNF PROS1 VDR
8 liver/biliary system MP:0005370 9.85 IL6 IL10 IL2 TNF PROS1 TGFB1
9 muscle MP:0005369 9.8 PROS1 ADRA1A IL6 IL10 TNF VDR
10 neoplasm MP:0002006 9.76 MSMB IL1B NKX3-1 IL2 IL6 IL10
11 reproductive system MP:0005389 9.56 MSMB NKX3-1 IL2 IL6 IL10 TNF
12 skeleton MP:0005390 9.17 IL6 IL10 IL1B NKX3-1 TNF VDR

Drugs & Therapeutics for Prostatitis

Drugs for Prostatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Cycloserine Approved Phase 4,Phase 3 68-41-7 401 6234
3
Methyltestosterone Approved Phase 4 58-18-4 6010
4
Testosterone Approved, Investigational Phase 4 58-22-0 6013
5
Testosterone enanthate Approved Phase 4 315-37-7 9416
6
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
7
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
8
Ciprofloxacin Approved, Investigational Phase 4,Phase 3 85721-33-1 2764
9
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Fosfomycin Approved Phase 4 23155-02-4 446987
12
Sulfamethoxazole Approved Phase 4 723-46-6 5329
13
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
14
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
15
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
16
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
17
Cefoxitin Approved Phase 4 35607-66-0 441199
18
Cilastatin Approved, Investigational Phase 4 82009-34-5 5280454 6435415
19
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
21
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
22
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
23 Prulifloxacin Investigational Phase 4,Phase 2 123447-62-1
24 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
25 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
27 Analgesics Phase 4,Phase 3,Phase 2
28 Anti-Anxiety Agents Phase 4,Phase 3
29 Anticonvulsants Phase 4,Phase 3
30 calcium channel blockers Phase 4,Phase 3
31 Calcium, Dietary Phase 4,Phase 3,Phase 2
32 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
33 Psychotropic Drugs Phase 4,Phase 3
34 Tranquilizing Agents Phase 4,Phase 3
35 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
36 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
37 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Antitubercular Agents Phase 4,Phase 3
39 Fluoroquinolones Phase 4,Phase 3,Phase 2
40 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
41 Permixon Phase 4,Phase 3
42 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2
43 Antimetabolites Phase 4,Phase 3
44 Renal Agents Phase 4,Phase 3,Phase 2
45 Anabolic Agents Phase 4
46 Androgens Phase 4,Early Phase 1
47 Antineoplastic Agents, Hormonal Phase 4
48 Hormone Antagonists Phase 4,Phase 3,Early Phase 1
49 Hormones Phase 4,Phase 3,Early Phase 1
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 Treatment of Chronic Bacterial Prostatitis Completed NCT02130713 Phase 4 Third generation fluoroquinolone
2 Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
3 TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
4 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication Completed NCT02246361 Phase 4
5 Botox as a Treatment for Interstitial Cystitis in Women Completed NCT00194610 Phase 4 Botox
6 Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms Recruiting NCT02252367 Phase 4 Tadalafil
7 Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy. Not yet recruiting NCT03228108 Phase 4 Ciprofloxacin;Trimethoprim/Sulfamethoxazole;Fosfomycin;Pivmecillinam/augmentin
8 Effectiveness of Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia) Suspended NCT00194636 Phase 4
9 Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Terminated NCT00194597 Phase 4 Viagra (sildenafil citrate)
10 Botox as a Treatment for Chronic Male Pelvic Pain Syndrome Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
11 Efficacy of Gralise® for Chronic Pelvic Pain Terminated NCT01678911 Phase 4 Gralise
12 Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli Terminated NCT02474706 Phase 4 Cefoxitin;imipenem
13 Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
14 Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS) Completed NCT00919893 Phase 3 Cernilton;Placebo
15 Efficacy Study of Acupuncture to Relieve Symptoms of Chronic Prostatitis Completed NCT00260637 Phase 2, Phase 3
16 An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis Completed NCT00402688 Phase 3 levofloxacin;levofloxacin;levofloxacin
17 A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis Completed NCT00236808 Phase 3 levofloxacin
18 Levofloxacin, Chronic Bacterial Prostatitis Completed NCT00277511 Phase 3 Levofloxacin
19 Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00103402 Phase 3 Alfuzosin
20 Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA) Completed NCT00169585 Phase 3 Levofloxacin oral tablets
21 Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO) Completed NCT00495651 Phase 3 Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis;Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis
22 Complementary and Alternative Medicine for Urological Symptoms(CAMUS) Completed NCT00603304 Phase 3 Saw Palmetto - first 24 weeks;Placebo - first 24 weeks;Saw Palmetto - weeks 24 - 48;Placebo - weeks 24 - 48;Saw Palmetto - weeks 48 - 72;Placebo - weeks 48 - 72
23 "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk Completed NCT00056407 Phase 3 Dutasteride;Placebo
24 Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment Completed NCT00090103 Phase 3 dutasteride 0.5mg once daily for 4 years;tamsulosin 0.4mg once daily for 4 years
25 JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3 Jalyn;Placebo
26 Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
27 Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin Withdrawn NCT02975570 Phase 3 Delamanid;Linezolid;Levofloxacin;Pyrazinamide;WHO MDR-TB regimen
28 Laparoscopic Prostatectomy for Chronic Prostatitis Unknown status NCT00775515 Phase 2
29 Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Completed NCT00740779 Phase 2 Silodosin 8 mg;Placebo;Silodosin 4 mg
30 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00701311 Phase 2 CC-10004
31 Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Completed NCT00529386 Phase 2 Botox;Lidocaine
32 An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis Completed NCT00826514 Phase 2 Tanezumab;Placebo
33 An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland Completed NCT00236990 Phase 2 pentosan polysulfate sodium
34 A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) Completed NCT01391338 Phase 2 ASP3652;Placebo
35 A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome Completed NCT00362752 Phase 2 Norfloxacin;Placebo
36 Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder Completed NCT00343356 Phase 2 Trement
37 Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
38 Prulifloxacin in Chronic Bacterial Prostatitis (CBP) Recruiting NCT03201796 Phase 2 Prulifloxacin 600 mg;Levofloxacin 500mg
39 Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Recruiting NCT03500159 Phase 2 AQX-1125 200 mg;Placebo
40 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
41 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2 Thalidomide
42 Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis Unknown status NCT00913315 Not Applicable tolterodine;tamsulosin;placebo
43 Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830 Not Applicable
44 Shocking Therapy for Chronic Pelvic Pain Syndrome Unknown status NCT01828996 Not Applicable
45 Effect of Pumpkin Seeds Phonophoresis on Chronic Non-bacterial Prostatitis Completed NCT03461263 Not Applicable
46 Non Interventional Study of Levofloxacin in Chronic Prostatitis Completed NCT02711943 Levofloxacin 500
47 Efficacy of Electromagnetic Stimulation Therapy for Chronic Prostatitis and Chronic Pelvic Pain Syndrome Completed NCT00922012 Not Applicable
48 Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome Completed NCT01826617
49 Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT01843946
50 Chronic Pelvic Pain Study of Individuals With Diagnoses or Symptoms of Interstitial Cystitis and/ or Chronic Prostatitis Completed NCT01098279

Search NIH Clinical Center for Prostatitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: prostatitis

Genetic Tests for Prostatitis

Anatomical Context for Prostatitis

MalaCards organs/tissues related to Prostatitis:

41
Prostate, Bone, Endothelial, Lymph Node, Testes, Lung, T Cells

Publications for Prostatitis

Articles related to Prostatitis:

(show top 50) (show all 27530)
# Title Authors Year
1
Ga-68-PSMA PET/CT in treatment-naA^ve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases? ( 29978529 )
2018
2
Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis. ( 29529997 )
2018
3
Effect of Essential Oil on Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Pilot Randomized Controlled Trial. ( 29948596 )
2018
4
Identification and preliminary study of immunogens involved in autoimmune prostatitis in human males. ( 29947032 )
2018
5
Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy. ( 29975957 )
2018
6
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. ( 29978216 )
2018
7
Expression of Prostate-Specific Membrane Antigen (PSMA) in Brain Glioma and its Correlation with Tumor Grade. ( 29731795 )
2018
8
Chronic reactive arthritis associated with prostatitis caused by<i>Neisseria meningitidis</i>. ( 29374652 )
2018
9
Anti-oxidants as chemopreventive agents in prostate cancer: A gap between preclinical and clinical studies. ( 29446748 )
2018
10
PPARI' Elicits Ligand-Independent Repression of Trefoil Factor Family to Limit Prostate Cancer Growth. ( 29187400 )
2018
11
Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study. ( 28624553 )
2018
12
Guided undersampling classification for automated radiation therapy quality assurance of prostate cancer treatment. ( 29377156 )
2018
13
Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. ( 29679999 )
2018
14
Volumetric-based image guidance is superior to marker-based alignments for stereotactic body radiotherapy of prostate cancer. ( 29450961 )
2018
15
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. ( 29293372 )
2018
16
Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer. ( 29979319 )
2018
17
Management of chronic prostatitis/chronic pelvic pain syndrome. ( 29875042 )
2018
18
Glucose metabolism during the acute prostate cancer treatment trajectory: The influence of age and obesity. ( 27998647 )
2018
19
Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer. ( 29977602 )
2018
20
68Ga-PSMA-HBED-CC-Avid Synchronous Urinary Bladder Paraganglioma in a Patient With Metastatic Prostate Carcinoma. ( 29916916 )
2018
21
A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models. ( 29981500 )
2018
22
PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy. ( 28924059 )
2018
23
Prostatic cyst in general practice: A case report and literature review. ( 29489699 )
2018
24
Informational needs during active surveillance for prostate cancer: A qualitative study. ( 28886974 )
2018
25
Heteronormativity and prostate cancer: A discursive paper. ( 28382781 )
2018
26
Chitosan membranes applied on the prostatic neurovascular bundles after nerve-sparing robot-assisted radical prostatectomy: a phase II study. ( 28710845 )
2018
27
TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways. ( 29449534 )
2018
28
Efficacy, Predictive Factors, and Prediction Nomograms for <sup>68</sup>Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. ( 29358059 )
2018
29
Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. ( 29254781 )
2018
30
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. ( 29980832 )
2018
31
Genome-Wide Methylation Patterns in Androgen-Independent Prostate Cancer Cells: A Comprehensive Analysis Combining MeDIP-Bisulfite, RNA, and microRNA Sequencing Data. ( 29324665 )
2018
32
Oncostatin M induces tumorigenic properties in non-transformed human prostate epithelial cells, in part through activation of signal transducer and activator of transcription 3 (STAT3). ( 29526757 )
2018
33
Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. ( 29138344 )
2018
34
FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-X<sub>L</sub> cell survival genes. ( 29357840 )
2018
35
The impact on oncologic outcomes after radical prostatectomy for prostate cancer of converting soft tissue margins at the apex and bladder neck from tumor positive to negative. ( 29978558 )
2018
36
Increased risk of a herpes zoster attack in patients receiving androgen deprivation therapy for prostate cancer. ( 28786220 )
2018
37
Gambogic Acid Induces Cell Apoptosis and Inhibits MAPK Pathway in PTEN<sup>-/-</sup>/p53<sup>-/-</sup>Prostate Cancer Cells In Vitro and Ex Vivo. ( 28578487 )
2018
38
Coatomer subunit beta 2 (COPB2), identified by label-free quantitative proteomics, regulates cell proliferation and apoptosis in human prostate carcinoma cells. ( 29129687 )
2018
39
Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients. ( 29150561 )
2018
40
New prostate cancer grade grouping system predicts survival after radical prostatectomy. ( 29447924 )
2018
41
Prostate-specific Membrane Antigen Imaging in Recurrent Medullary Thyroid Cancer: A New Theranostic Tracer in the Offing? ( 29962733 )
2018
42
Malignant invasion of the central nervous system: the hidden face of a poorly understood outcome of prostate cancer. ( 29980839 )
2018
43
The Impact of<sup>68</sup>Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. ( 28646014 )
2018
44
Prostate-specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma. ( 29873168 )
2018
45
Involvement of prostatic interstitial cells of Cajal in inflammatory cytokines-elicited catecholamines production: Implications for the pathophysiology of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). ( 29649477 )
2018
46
Injection therapy for chronic prostatitis: A retrospective analysis of 77 cases. ( 29633789 )
2018
47
Treatment of refractory category III nonbacterial chronic prostatitis/chronic pelvic pain syndrome with intraprostatic injection of onabotulinumtoxinA: a prospective controlled study. ( 29680006 )
2018
48
Tardive Dyskinesia: Is Vitamin E Singing the Prostate Blues? ( 29701932 )
2018
49
Combined prostatic urethral lift and remodeling of the prostate and bladder neck: a modified transurethral approach in the treatment of symptomatic lower urinary tract obstruction. ( 29450732 )
2018
50
Reversible intrahepatic cholestasis in metastatic prostate cancer: An uncommon paraneoplastic syndrome. ( 29541472 )
2018

Variations for Prostatitis

Expression for Prostatitis

Search GEO for disease gene expression data for Prostatitis.

Pathways for Prostatitis

Pathways related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 CXCL8 IL10 IL1B IL2 IL6 TGFB1
2
Show member pathways
13.48 CXCL8 IL10 IL1B IL2 IL6 TGFB1
3
Show member pathways
13.39 CXCL8 IL10 IL1B IL2 IL6 TGFB1
4
Show member pathways
13.33 CXCL8 IL10 IL1B IL2 IL6 TGFB1
5
Show member pathways
13.28 CXCL8 IL10 IL1B IL2 IL6 TGFB1
6
Show member pathways
13.03 CXCL8 IL10 IL1B IL2 IL6 TGFB1
7
Show member pathways
12.9 CXCL8 IL10 IL1B IL2 IL6 TGFB1
8 12.85 CXCL8 IL2 IL6 KLK3 NKX3-1 TGFB1
9
Show member pathways
12.79 CXCL8 IL1B IL2 IL6 TNF
10
Show member pathways
12.7 IL1B IL2 IL6 TGFB1 TNF
11
Show member pathways
12.66 CXCL8 IL10 IL1B IL2 IL6 TNF
12
Show member pathways
12.6 IL10 IL1B IL2 IL6 TNF
13
Show member pathways
12.55 CXCL8 IL6 TGFB1 TNF
14 12.54 IL10 IL1B IL2 TNF
15
Show member pathways
12.47 IL10 IL1B IL2 IL6 TGFB1 TNF
16
Show member pathways
12.44 IL10 IL1B IL2 IL6 TGFB1 TNF
17 12.42 IL2 IL6 TGFB1 TNF
18
Show member pathways
12.34 IL1B IL2 IL6 TNF
19
Show member pathways
12.34 CXCL8 IL1B IL6 TNF
20
Show member pathways
12.28 CXCL8 IL1B IL6 TNF
21
Show member pathways
12.27 IL10 IL1B TGFB1 TNF
22
Show member pathways
12.26 IL10 IL1B IL2 IL6 TNF
23
Show member pathways
12.26 IL10 IL1B IL2 IL6 TGFB1 TNF
24
Show member pathways
12.23 CXCL8 IL1B IL6 TNF
25 12.22 IL10 IL1B IL6 TGFB1 TNF VDR
26
Show member pathways
12.2 CXCL8 IL1B IL6 TNF
27
Show member pathways
12.12 CXCL8 IL10 IL1B IL2 IL6 TGFB1
28 12.12 CXCL8 IL10 IL1B IL6 NKX3-1 TNF
29
Show member pathways
12.08 IL6 KLK3 TGFB1
30
Show member pathways
12.05 IL10 IL6 TGFB1
31 12.03 IL6 TGFB1 TNF
32 12.02 IL1B TGFB1 TNF
33 12.02 IL10 IL2 IL6 TNF
34 11.98 CXCL8 IL1B IL6 TGFB1
35 11.94 IL1B IL6 TNF
36 11.94 CXCL8 IL1B IL6 TGFB1 TNF
37 11.92 CXCL8 IL1B IL2 IL6 TGFB1 TNF
38 11.89 IL1B IL6 TNF
39 11.89 CXCL8 IL1B IL6 TGFB1 TNF
40 11.88 CXCL8 IL1B TNF
41 11.87 CXCL8 IL2 TGFB1
42 11.86 IL10 IL2 IL6
43
Show member pathways
11.86 CXCL8 IL6 TGFB1
44 11.86 CXCL8 IL10 IL1B IL6 TGFB1 TNF
45 11.85 IL10 IL1B IL2 TNF
46 11.83 CXCL8 IL1B IL6
47 11.81 CXCL8 IL2 IL6
48 11.8 CXCL8 IL10 IL1B IL6 TNF
49
Show member pathways
11.77 CXCL8 IL2 TNF
50 11.72 CXCL8 IL10 IL1B IL6 TGFB1 TNF

GO Terms for Prostatitis

Cellular components related to Prostatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CXCL8 IL10 IL1B IL2 IL6 KLK3
2 secretory granule GO:0030141 9.33 IL1B KLK3 TGFB1
3 extracellular space GO:0005615 9.32 CXCL8 IL10 IL1B IL2 IL6 KLK3

Biological processes related to Prostatitis according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.99 CXCL8 IL10 IL1B IL2 IL6 TNF
2 MAPK cascade GO:0000165 9.97 IL1B IL2 TGFB1 TNF
3 inflammatory response GO:0006954 9.95 CXCL8 IL10 IL1B IL6 TGFB1 TNF
4 leukocyte migration GO:0050900 9.93 IL1B PROS1 TGFB1 TNF
5 positive regulation of gene expression GO:0010628 9.93 IL1B IL6 NKX3-1 TGFB1 TNF VDR
6 response to organic substance GO:0010033 9.86 IL10 TGFB1 TNF
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 IL1B IL6 TGFB1 TNF
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.85 IL6 TGFB1 TNF
9 cellular response to organic cyclic compound GO:0071407 9.83 IL1B TGFB1 TNF
10 response to glucocorticoid GO:0051384 9.83 IL10 IL6 TNF
11 positive regulation of DNA binding transcription factor activity GO:0051091 9.83 IL10 IL1B IL6 TNF
12 positive regulation of protein phosphorylation GO:0001934 9.83 IL1B IL2 NKX3-1 TGFB1 TNF
13 positive regulation of T cell proliferation GO:0042102 9.82 IL1B IL2 IL6
14 positive regulation of interleukin-6 production GO:0032755 9.79 IL1B IL6 TNF
15 positive regulation of cell division GO:0051781 9.78 IL1B NKX3-1 TGFB1
16 negative regulation of fat cell differentiation GO:0045599 9.77 IL6 TGFB1 TNF
17 positive regulation of interferon-gamma production GO:0032729 9.77 IL1B IL2 TNF
18 lipopolysaccharide-mediated signaling pathway GO:0031663 9.72 IL1B TGFB1 TNF
19 cellular response to lipopolysaccharide GO:0071222 9.72 CXCL8 IL10 IL6 TNF VDR
20 positive regulation of chemokine production GO:0032722 9.71 IL6 TNF
21 positive regulation of histone acetylation GO:0035066 9.71 IL1B TGFB1
22 embryonic digestive tract development GO:0048566 9.7 CXCL8 TNF
23 negative regulation of lipid catabolic process GO:0050995 9.7 IL1B TNF
24 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.7 IL1B TNF
25 regulation of regulatory T cell differentiation GO:0045589 9.7 IL2 TGFB1
26 regulation of signaling receptor activity GO:0010469 9.7 CXCL8 IL10 IL1B IL2 IL6 TGFB1
27 negative regulation of growth of symbiont in host GO:0044130 9.69 IL10 TNF
28 response to molecule of bacterial origin GO:0002237 9.69 CXCL8 IL10
29 positive regulation of interleukin-17 production GO:0032740 9.69 IL2 TGFB1
30 positive regulation of immunoglobulin secretion GO:0051024 9.68 IL2 IL6
31 positive regulation of regulatory T cell differentiation GO:0045591 9.68 IL2 TGFB1
32 negative regulation of lipid storage GO:0010888 9.67 IL6 TNF
33 positive regulation of chemokine biosynthetic process GO:0045080 9.67 IL1B TNF
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 IL1B TNF
35 protein kinase B signaling GO:0043491 9.67 IL1B NKX3-1 TGFB1 TNF
36 endothelial cell apoptotic process GO:0072577 9.66 IL10 TNF
37 regulation of establishment of endothelial barrier GO:1903140 9.65 IL1B TNF
38 negative regulation of cytokine secretion involved in immune response GO:0002740 9.64 IL10 TNF
39 positive regulation of fever generation GO:0031622 9.63 IL1B TNF
40 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.62 NKX3-1 TNF
41 sequestering of triglyceride GO:0030730 9.61 IL1B TNF
42 receptor biosynthetic process GO:0032800 9.58 IL10 TNF
43 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 IL1B TNF
44 positive regulation of mononuclear cell migration GO:0071677 9.57 TGFB1 TNF
45 negative regulation of mitotic cell cycle GO:0045930 9.56 IL10 NKX3-1 TGFB1 TNF
46 cytokine-mediated signaling pathway GO:0019221 9.5 CXCL8 IL10 IL1B IL2 IL6 TGFB1
47 negative regulation of cell proliferation GO:0008285 9.23 ADRA1A CXCL8 IL10 IL1B IL6 NKX3-1
48 positive regulation of cell proliferation GO:0008284 10.04 IL1B IL2 IL6 NKX3-1 TGFB1
49 positive regulation of transcription, DNA-templated GO:0045893 10.01 IL10 IL1B IL6 NKX3-1 TGFB1 TNF
50 positive regulation of transcription by RNA polymerase II GO:0045944 10.01 IL10 IL1B IL2 IL6 NKX3-1 TGFB1

Molecular functions related to Prostatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL10 IL2 IL6 TGFB1
2 cytokine activity GO:0005125 9.17 CXCL8 IL10 IL1B IL2 IL6 TGFB1

Sources for Prostatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....